Pacific Biosciences of California Prices Public Offering

Pacific Biosciences of California Prices Public Offering

Pacific Biosciences of California has priced its previously announced underwritten public offering of 15,419,354 shares of its common stock at a price of $3.10 per share, equal to a 7.2% discount relative to the stock’s Wednesday closing price. Shares of Pacific Biosciences of California were down 8.7% in recent pre-market trading. Net proceeds of the offering are expected to be approximately $45.9 million, and the offering is expected to close […]

Read More ˃
Futures Trade Lower as Mueller Likely to Open Investigation Into Trump

Futures Trade Lower as Mueller Likely to Open Investigation Into Trump

Stock futures were losing ground ahead of Thursday’s open as political turmoil weighs on Wall Street. The Washington Post reported late Wednesday that special counsel Robert Mueller may open an investigation against president Trump for obstruction of justice. As a result, Dow futures were 78 points below fair value while another sell-off in tech stocks is setting the Nasdaq Composite up for a bruising at the open. At 8:30 am […]

Read More ˃
TransEnterix Sells Robotic Surgery System to Medical University in Tokyo;

TransEnterix Sells Robotic Surgery System to Medical University in Tokyo;

TransEnterix (TRXC), a medical device maker using robotics, disclosed early Thursday the sale of a surgery system to the Saitama Medical University International Medical Center in Tokyo, Japan. Shares rose more than 3% in pre-market. The Senhance robotic surgery system was purchased under a physician import license, which allows medical devices to be directly purchased by Japanese physicians, the company said in a statement. Details of the purchasing price were […]

Read More ˃
Renesola Tops Q1 Street View On Revenues; Shy On Earnings; Up 19% Pre-Bell

Renesola Tops Q1 Street View On Revenues; Shy On Earnings; Up 19% Pre-Bell

Renesola (SOL) Thursday reported a Q1 loss that was wider-than-expected on revenues above Street views and issued downside Q2 revenue guidance. The solar-power project company traded up 19.1% pre-bell. Renesola reported a loss of $1.16 per American depositary share, wider than the $1.08 Street view of two analysts compiled by Capital IQ. A year ago the company reported a gain of $0.06. The company reported Q1 revenues of $156.6 million, […]

Read More ˃
Myriad Genetics’ Subsidiary Crescendo Says Data Shows High Vectra DA Score More Predictive of RA Damage

Myriad Genetics’ Subsidiary Crescendo Says Data Shows High Vectra DA Score More Predictive of RA Damage

Myriad Genetics’ (MYGN) wholly-owned subsidiary Crescendo Bioscience said Thursday new data from a meta-analysis of clinical studies and a registry demonstrating the ability of the Vectra DA test to predict joint damage were presented at the 2017 European League Against Rheumatism meeting in Madrid, Spain. The key finding is that high Vectra DA score is associated with significantly increased risk of joint damage progression in a variety of patients with […]

Read More ˃